EVIIVE develops single extracellular vesicle-based diagnostics to predict immunotherapy response and monitor tumor microenvironment in real time. Our platform integrates advanced flow analytics and machine learning for precision oncology applications.
Products, services, technology
EVIIVE develops single extracellular vesicle (EV) diagnostics for immunotherapy response prediction. Our platform integrates high-dimensional flow cytometry and proprietary algorithms to deliver decentralized, clinically actionable companion diagnostics.
Cooperation possibilities
We welcome collaborations with clinical partners, pharma, diagnostic labs, and investors. We are seeking co-development, pilot testing, licensing opportunities, and strategic funding to accelerate commercialization of our EV-based diagnostic platform.
- https://www.eviive.ch
- +41 76 712 41 47
- Send an email
- Kevin Ho Wai Yim
Some insights
EVIIVE aims to transform cancer care by enabling personalized immunotherapy decisions through innovative liquid biopsy diagnostics, improving patient outcomes while reducing unnecessary treatments and healthcare burden.
We’re pioneering a science-first approach to solve one of the toughest problems in oncology—bringing personalized treatment decisions to more patients through truly novel biomarker technology.
Companies like Genentech, Foundation Medicine, and Tempus who have translated complex science into impactful patient solutions while setting benchmarks in precision oncology.
Our strength lies in deep scientific and clinical expertise. We’re seeking to expand with talent in commercial strategy, regulatory affairs, and data-driven health economics.
We read cancer blood like tea leaves to tell who will respond to therapy, and then spend hours explaining that to others.
By facilitating funding access, providing translational research infrastructure, and supporting strategic partnerships with pharma, diagnostics, and regulatory experts.
We seek to connect with pharma CDx teams, hospital labs, translational oncology KOLs, digital health platforms, and seed-to-Series A investors.